Table 2. Demographic characteristics and molecular markers in urinary cells from patients with benign bladder histology.
| Molecular markers | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient ID | Sex/Age | Pathology | First visit/Follow-up (initial diagnosis) | FGFR3 | BCL2 | CCNA1 | EOMES | HOXA9 | POU4F2 | SALL3 | VIM |
| 62 | M/71 | Inflammation | First visit | WT | U | U | U | U | U | U | U |
| 66 | M/64 | Normal bladder | Follow-up (LG, Ta) | WT | U | M | U | U | U | U | U |
| 68 | M/83 | Normal bladder | Follow-up (LG, Ta) | WT | M | M | U | M | U | U | U |
| 70 | K/80 | Glandular metaplasia | First visit | WT | U | U | U | U | U | U | U |
| 82 | M/77 | Normal bladder | First visit | WT | U | U | U | U | U | U | M |
| 84 | M/71 | Normal bladder | Follow-up (Tis) | WT | U | M | U | M | U | U | U |
| 85 | M/74 | Normal bladder | First visit | WT | U | U | U | U | U | U | U |
| 86 | M/75 | Inflammation | Follow-up (LG, Ta + Tis) | WT | U | U | U | U | U | U | U |
| 87 | K/41 | Inflammation | First visit | WT | U | U | U | U | U | M | U |
| 90 | M/74 | Chronic inflammation | First visit | WT | U | U | U | U | M | M | U |
| 91 | K/74 | Chronic inflammation | Follow-up (T1 + Tis) | WT | U | U | U | U | U | U | U |
| 93 | M/50 | Chronic inflammation | First visit | WT | U | U | U | U | U | U | U |
| 100 | M/59 | Inverted papilloma | First visit | WT | U | U | U | U | U | U | U |
| 101 | K/53 | Normal bladder | First visit | WT | U | U | U | U | U | U | U |
| 102 | M/49 | Normal bladder | First visit | WT | M | U | U | U | M | U | U |
| 103 | K/78 | Normal bladder | First visit | WT | M | M | M | U | M | M | U |
| 105 | M/46 | Inflammation | First visit | WT | U | U | U | U | U | M | U |
| 108 | M/68 | Chronic inflammation | Follow-up (T1 + Tis) | WT | U | U | U | U | U | U | U |
| 109 | M/42 | Inflammation | First visit | WT | U | U | U | U | U | U | U |
| 114 | M/71 | Inflammation | Follow-up (LG, Ta) | WT | U | M | U | U | M | M | M |
| *116 | M/84 | Inflammation | Follow-up (LG, Ta) | S249C | M | M | U | M | U | M | M |
| 117 | K/74 | Inflammation | Follow-up (LG, Ta) | WT | U | U | U | U | M | U | M |
| 118 | K/49 | Normal bladder | First visit | WT | U | U | U | U | U | U | U |
| 122 | M/74 | Inflammation | Follow-up (HG, Ta + Tis) | WT | U | U | U | U | U | U | U |
| 125 | M/45 | Inflammation | Follow-up (LG, Ta + Tis) | WT | U | U | U | U | U | M | U |
| 129 | M/74 | Inflammation | Follow-up (Tis) | WT | U | U | U | U | U | U | U |
*, Patient diagnosed with a low-grade Ta tumor 6 months after a negative TURB result.
LG, low grade. HG, high grade. Tis, tumor in situ. WT, wild type. M, hypermethylated. U, unmethylated.